Clinical trial NCT05762523 - References

Smallpox — Safety and Tolerability Study of the VAC∆6 Vaccine in Volunteers Aged 18-40 Years

Citation(s)

•   Kolosova IV, Babkina IN, Yakubitsky SN, Maksyutov RA, Safronov PF, Shchelkunov SN
  Recombinant strain L-IVP 1421ABJCN of vaccinia virus with deleted virulence genes A56R, B8R, J2R, C3L, N1L to obtain a live cell-based attenuated vaccine against smallpox and other orthopoxviruses pathogenic to humans. RF Patent No. 2588388, priority 20.04.2015 (in Russian)
•   Maksyutov RA, Yakubitskiy SN, Kolosova IV, Tregubchak TV, Shvalov AN, Gavrilova EV, Shchelkunov SN
  Genome stability of the vaccine strain VACDelta6. Vavilovskii Zhurnal Genet Selektsii. 2022 Jul;26(4):394-401. doi: 10.18699/VJGB-22-48.
•   Maksyutov RA, Yakubitskyi SN, Kolosova IV, Shchelkunov SN
  Comparing New-Generation Candidate Vaccines against Human Orthopoxvirus Infections. Acta Naturae. 2017 Apr-Jun;9(2):88-93.
•   Marennikova SS, Shchelkunov SN
  Orthopoxviruses pathogenic for humans (monograph). KMK Scientific Press Ltd.1998; 386 p. (in Russian).
•   Olson VA, Shchelkunov SN
  Are We Prepared in Case of a Possible Smallpox-Like Disease Emergence? Viruses. 2017 Aug 27;9(9):242. doi: 10.3390/v9090242.
•   Shchelkunov SN, Shchelkunova GA
  [We should be prepared to smallpox re-emergence.]. Vopr Virusol. 2019;64(5):206-214. doi: 10.36233/0507-4088-2019-64-5-206-214. Russian.
•   Shchelkunov SN, Shchelkunova GA
  Genes that Control Vaccinia Virus Immunogenicity. Acta Naturae. 2020 Jan-Mar;12(1):33-41. doi: 10.32607/actanaturae.10935.
•   Shchelkunova GA, Shchelkunov SN
  40 Years without Smallpox. Acta Naturae. 2017 Oct-Dec;9(4):4-12.
•   Yakubitskiy SN, Kolosova IV, Maksyutov RA, Shchelkunov SN
  Attenuation of Vaccinia Virus. Acta Naturae. 2015 Oct-Dec;7(4):113-21.
•   Yakubitsky SN, Kolosova IV, Maksyutov RA, Shchelkunov SN
  Recombinant strain VAC?6 of vaccinia virus with deleted virulence genes C3L, N1L, J2R, A35R, A56R, B8R for obtaining a live cell-based attenuated vaccine against smallpox and other human orthopoxvirus infections. RF Patent No. 2621868, priority 24.06.2016 (in Russian).
•   Yakubitskyi SN, Kolosova IV, Maksyutov RA, Shchelkunov SN
  Highly immunogenic variant of attenuated vaccinia virus. Dokl Biochem Biophys. 2016;466:35-8. doi: 10.1134/S1607672916010105. Epub 2016 Mar 31.

An Open-label Controlled Study of the Safety and Tolerability of the Live Cell-based Vaccine Against Smallpox and Other Orthopoxvirus Infections (VAC∆6 Vaccine) Based on Vaccinia Virus, in Volunteers Aged 18-40 Years

Details for clinical trial NCT05762523